Full Press Release Details
Tiziana Life Sciences plc
("Tiziana" or the "Company")
Tiziana files Registration Statement
on Form F-3 with U.S. Securities and Exchange Commission
New York / London, January 27, 2021
- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology,
inflammation, and infectious diseases, today announces that it has filed a "universal" shelf registration statement
on Form F-3 (File No. 333-252441) (the "Registration Statement") with the U.S. Securities and Exchange Commission
("SEC") in relation to up to US$250,000,000 in market value of its securities.
The filing of "universal" shelf
registration statements of this type, a common practice by NASDAQ-listed companies, enables issuers to have more timely and efficient
access to the U.S. capital markets.
The Registration Statement also contains
a preliminary prospectus supplement relating to an "at-the-market" sales agreement, which the Company expects to enter
into with B. Riley Securities, Inc. (the "Agent") on or about the date of this announcement, pursuant to which
the Company may sell, from time to time, at its option, up to US$100,000,000 (i.e., up to 40% of those securities registered pursuant
to the Registration Statement) in market value of American Depositary Shares representing its ordinary shares through the Agent
(the "ATM Program").
For the avoidance of doubt, the Company
has no immediate plans to offer or sell any securities pursuant to the Registration Statement or the ATM Program.
The Company notes that the Registration
Statement has not yet been declared effective by the SEC, and that the specifics of any future offering pursuant to the Registration
Statement (including under the ATM Program), such as the prices and terms of the securities offered, will be determined at the
time of any such offering and will be described in detail in a prospectus supplement filed by the Company with the SEC in connection
For further enquiries:
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder
RedChip Companies Inc.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a dual listed
(NASDAQ: TLSA & LSE: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat
human diseases in oncology, inflammation and infectious diseases. In addition to milciclib, the Company will be shortly initiating
Phase 2 studies with orally administered Foralumab for Crohn's Disease and nasally administered Foralumab for progressive multiple
sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world. This Phase
2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn's Disease, multiple
sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell
response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal
antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.
Important legal information
This announcement shall not constitute
an offer to sell or the solicitation of an offer to buy any Securities, nor shall there be any sale of any Securities in any state
or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities
laws of any such state or jurisdiction.
Neither this announcement nor the Registration
Statement forms part of an offer of transferable securities to the public in the United Kingdom and no prospectus has been, or
is required to be, submitted to the UK Financial Conduct Authority for approval. The filing of the Registration Statement with
the SEC does not affect the statutory pre-emption rights of shareholders in the Company.
The securities registered pursuant to the
Registration Statement may not be sold nor may offers to buy be accepted prior to the time the Registration Statement becomes effective.
The filing of the Registration Statement does not affect the statutory pre-emption
rights of shareholders in the Company.
A copy of the Registration Statement may
be obtained on the SEC's website at www.sec.gov.